BIIB » Topics » Strategic Investments

This excerpt taken from the BIIB 10-Q filed Apr 17, 2009.
Strategic Investments
 
We hold investments in equity securities of certain publicly traded companies. For the three months ended March 31, 2009 and 2008, we recognized $0.4 million and $2.7 million, respectively, in charges for the impairment of strategic investments that were deemed to be other-than-temporary. Strategic investments are included in investments and other assets on the accompanying consolidated balance sheet.
 
This excerpt taken from the BIIB 10-K filed Feb 6, 2009.
Strategic Investments
 
In 2007, we sold our share in one strategic investment for $99.5 million, which resulted in a $17.2 million gain. In 2008 and 2006, we did not sell any portion of strategic investments. Strategic investments are included in investments and other assets on the accompanying balance sheet.
 
In 2008, 2007, and 2006, we recognized $8.6 million, $16.0 million, and $30.5 million in charges, respectively, for the impairment of publicly-held strategic investments for declines in value that were determined to be other-than-temporary.
 
We hold other investments in equity securities of certain privately held biotechnology companies or biotechnology oriented venture capital funds. The cost basis of these securities at December 31, 2008 and 2007 is $64.7 million and $52.9 million, respectively. These securities are included in investments and other assets on the accompanying consolidated balance sheet.
 
In 2008, 2007, and 2006, we recorded $2.3 million, $2.4 million, and $3.9 million, respectively, in charges for the impairment for certain investments in privately held companies or funds that were determined to be other than temporary.
 
This excerpt taken from the BIIB 10-Q filed Oct 21, 2008.
Strategic Investments
 
We hold investments in equity securities of certain publicly traded companies. In the three and nine months ended September 30, 2008, we recognized $2.5 million and $6.1 million, respectively, in charges for the impairment of strategic investments that were deemed to be other-than-temporary. In the nine months ended September 30, 2007, we recognized no charges for the impairment of strategic investments that were deemed to be other-than-temporary.
 
This excerpt taken from the BIIB 10-Q filed Jul 22, 2008.
Strategic Investments
 
In the three and six months ended June 30, 2008, we recognized $0.9 million and $3.6 million, respectively, in charges for the impairment of strategic investments that were deemed to be other-than-temporary. In the six months ended June 30, 2007, we recognized no charges for the impairment of strategic investments that were deemed to be other-than-temporary.
 
This excerpt taken from the BIIB 10-Q filed Apr 23, 2008.
Strategic Investments
 
In the three months ended March 31, 2008, we recognized $2.7 million in charges for the impairment of investments that were deemed to be other-than-temporary. In the three months ended March 31, 2007, we recognized no charges for the impairment of investments that were deemed to be other-than-temporary.
 
This excerpt taken from the BIIB 10-K filed Feb 14, 2008.
Strategic Investments
 
In 2007, we sold our share in one strategic investment for $99.5 million, which resulted in an $17.2 million gain. In 2006 and 2005, we did not sell any portion of strategic investments. Strategic investments are included in investments and other assets on the accompanying balance sheet.
 
In 2007, 2006 and 2005, we recognized $16.0 million, $30.5 million and $13.8 million in charges, respectively, for the impairment of strategic investments for declines in value that were determined to be other-than-temporary.
 
We hold other investments in equity securities of certain privately held biotechnology companies or biotechnology oriented venture capital funds. The cost basis of these securities at December 31, 2007 and 2006 is $52.9 million and $32.6 million, respectively. These securities are included in investments and other assets on the accompanying consolidated balance sheet.
 
In 2007, 2006 and 2005, we recorded $2.4 million, $3.9 million and $1.6 million, respectively, in charges for the impairment for certain of those investments that were determined to be other than temporary.
 
This excerpt taken from the BIIB 10-Q filed Oct 23, 2007.
Strategic Investments
 
In the nine months ended September 30, 2007, we recognized no charges for the impairment of investments that were deemed to be other than temporary. In June 2007, we sold a portion of our share in one strategic investment for $48.2 million, which resulted in an $8.1 million gain. In July 2007, we sold the remaining portion of this strategic investment for $50.7 million, which resulted in a gain of $9.1 million, resulting in a total gain of approximately $17.2 million in 2007. In the three and nine months ended September 30, 2006, we recognized $0.6 million and $5.0 million in charges, respectively, for the impairment of strategic investments that were deemed to be other than temporary.
 
This excerpt taken from the BIIB 10-Q filed Jul 24, 2007.
Strategic Investments
 
In the three and six months ended June 30, 2007, we recognized no charges for the impairment of investments that were deemed to be other than temporary. In June 2007, we sold 49% of our share in one strategic investment for $48.2 million, which resulted in an $8.1 million gain. In July 2007, we sold the remaining portion of this strategic investment for $50.7 million, which resulted in an additional gain of approximately $9.1 million. In the three and six months ended June 30, 2006, we recognized $2.3 million and $4.4 million in charges, respectively, for the impairment of investments that were deemed to be other than temporary.
 
This excerpt taken from the BIIB 10-K filed Feb 21, 2007.
Strategic Investments
 
In 2006, 2005, and 2004 we recognized $30.5 million, $13.8 million, and $12.7 million in charges, respectively, for the impairment of investments that were determined to be other-than-temporary following a decline in value of the strategic investment.
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki